OSBANT

Product Overview

About OSBANT

OSBANT is a prescription medication used to treat and prevent osteoporosis in post‑menopausal women and men at risk of fractures. The drug contains the active ingredient ibandronate de sodium, a bisphosphonate that reduces bone resorption and improves bone density. OSBANT is administered orally once a month, providing a convenient dosing schedule for patients who may have difficulty with daily medication. The formulation is designed to be taken on an empty stomach with a full glass of water, and patients should remain upright for at least 30 minutes after ingestion to reduce the risk of esophageal irritation. The medication is available in tablet form and is supplied in a blister pack that contains 12 tablets for a one‑month supply. OSBANT is part of a broader class of bisphosphonates that work by binding to bone mineral and inhibiting osteoclast activity, thereby slowing bone loss and reducing the likelihood of fractures.

Key Benefits & Uses

• Reduces the risk of vertebral and non‑vertebral fractures in patients with osteoporosis.
• Improves bone mineral density, leading to stronger bones over time.
• Convenient once‑monthly dosing enhances patient adherence and reduces the burden of daily medication.

Active Ingredient & Action

The active ingredient, ibandronate de sodium, is a nitrogen‑containing bisphosphonate that binds to hydroxyapatite in bone. By inhibiting the enzyme farnesyl diphosphate synthase in osteoclasts, it decreases bone resorption and promotes a net gain in bone mass. This mechanism helps to restore bone strength and reduce the incidence of fractures in individuals with low bone density.

Important Notes

Patients should inform their healthcare provider of any history of esophageal disorders, kidney disease, or difficulty swallowing, as these conditions may affect the safety and efficacy of OSBANT. The medication should not be taken with dairy products, antacids, or other calcium supplements within 30 minutes of dosing. Regular monitoring of bone density and kidney function is recommended during long‑term therapy. If a patient experiences persistent abdominal pain, nausea, or signs of esophageal irritation, they should seek medical attention promptly. OSBANT is not intended for use in patients with severe renal impairment or for the treatment of bone metastases.